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Subjects and Methods

Series of Patients with GHIS
A series of 27 patients with GHIS has been assembled by Pharmacia (Kabi Peptide Hormones), Stockholm, Sweden (6). These subjects have all been demonstrated to have the typical clinical and endocrine features of GHIS, fulfilling accepted criteria for this diagnosis (5) . Unlike previous series of GHIS patients, either from Israel (9) or Ecuador (10), this series is geographically and genetically heterogeneous.
Clinical features
The 27 patients were resident in: Australia (n=1), Belgium (n=2), Denmark (n=1), France (n=7), Germany (n=1), Italy (n=3), Spain (n=3), Slovenia (n=1) and United Kingdom (n=8). Clinical details are shown in Table 1 . Twelve patients were male and 15 female. Parental consanguinity was present in the cases of 3 subjects and the series contained 2 pairs of siblings. Birth weights for gestational age (n=26) were: median -0.72 SDS, range 1.75 to -3.29. Birth lengths for gestational age (n=13) were: median -1.59, range 0.63 to -3.63. Eight patients had experienced hypoglycaemia and 7 out of the 12 patients had micropenis.
Auxological features
The severity of growth failure varied considerably (Fig. 1) . The median height SDS value was: -6.0, range -3.2 to -8.9. Median sitting height (n=20) was: -6.1 SDS, range -3.8 to -10.2. Median weight SDS was: -3.2, range -0.1 to -5.2. 
Conclusion
Recombinant IGF-I currently provides the only therapeutic option in patients with GHIS. A definite effect on linear growth has been demonstrated in these patients, however the optimal dose regimen has still to be defined. The presence of lipolytic and anabolic effects also demonstrate that IGF-I is a potent new therapeutic agent. Longer term studies to determine whether the extreme short stature which exists in adult life in subjects with GHIS may ultimately be preventable with long-term replacement therapy with recombinant IGF-I are currently being performed. It is important to remember that at the time of writing this paper, the world experience of IGF-I therapy amounts to a little more than 2 years. Consequently a great deal still needs to be learned about this new form of therapy.
